| __timestamp | ACADIA Pharmaceuticals Inc. | Eli Lilly and Company |
|---|---|---|
| Wednesday, January 1, 2014 | 32748000 | 6620800000 |
| Thursday, January 1, 2015 | 90804000 | 6533000000 |
| Friday, January 1, 2016 | 186456000 | 6452000000 |
| Sunday, January 1, 2017 | 255062000 | 6588100000 |
| Monday, January 1, 2018 | 265758000 | 5975100000 |
| Tuesday, January 1, 2019 | 325638000 | 6213800000 |
| Wednesday, January 1, 2020 | 388661000 | 6121200000 |
| Friday, January 1, 2021 | 396028000 | 6431600000 |
| Saturday, January 1, 2022 | 369090000 | 6440400000 |
| Sunday, January 1, 2023 | 402466000 | 6941200000 |
| Monday, January 1, 2024 | 8593800000 |
Unlocking the unknown
In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. This analysis compares the SG&A efficiency of Eli Lilly and Company with ACADIA Pharmaceuticals Inc. over a decade, from 2014 to 2023.
Eli Lilly, a giant in the industry, consistently reported SG&A expenses averaging around $6.4 billion annually. Despite fluctuations, their expenses remained relatively stable, showcasing a robust cost management strategy. In contrast, ACADIA Pharmaceuticals, a smaller player, saw a significant rise in SG&A expenses, increasing by over 1,100% from 2014 to 2023. This surge reflects ACADIA's aggressive expansion and investment in market presence.
Understanding these trends offers valuable insights into each company's strategic priorities and operational efficiencies, highlighting the diverse approaches within the pharmaceutical sector.
Eli Lilly and Company vs Intra-Cellular Therapies, Inc.: SG&A Expense Trends
Eli Lilly and Company or Insmed Incorporated: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Eli Lilly and Company or Viatris Inc.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Sarepta Therapeutics, Inc.
Breaking Down SG&A Expenses: Eli Lilly and Company vs CymaBay Therapeutics, Inc.
Eli Lilly and Company vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
AbbVie Inc. and ACADIA Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Vertex Pharmaceuticals Incorporated and ACADIA Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: GSK plc vs ACADIA Pharmaceuticals Inc. Trends and Insights
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs ACADIA Pharmaceuticals Inc.
Breaking Down SG&A Expenses: ACADIA Pharmaceuticals Inc. vs Merus N.V.
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and Ligand Pharmaceuticals Incorporated